Ferinject Clinical Trials

3 actively recruiting trials

No change since May 2026

Also known as: Ferric carboxymaltose, IV FCM

Pipeline

Phase 3: 1Phase 4: 2

Top Sponsors

Wroclaw Medical University1
Tomsk National Research Medical Center of the Russian Academy of Sciences1
Asan Medical Center1

Indications

Heart Disease2
Iron Deficiency, Latent1
Myocardial Infarction, Acute1
Chronic Heart Failure1
Advanced Gastric Carcinoma1

Other3 trials

Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

Phase 4

Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)

Phase 3

The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.